#obesity drugs
3 stories
Bayer Targets GLP-1 Side Effect Solutions for India
Bayer plans to launch products addressing GLP-1 drug side effects in India by 2030.
The Economic Times · 1m
Novo Nordisk Stock Drops 7% After Growth Plan Fails to Ease Competition Fears
Novo Nordisk's stock falls 7% as its post-Wegovy growth plan fails to reassure investors about competition risks
24/7 Wall St. · 1m
Wells Fargo's margin finally beats the bar
A small net interest margin win, a Berenberg upgrade for Lilly's spending spree, and a Fed meeting hanging over it all.
CNBC · 2m